Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Valdecoxib is an orally administered, highly selective cyclo-oxygenase (C0X)-2 inhibitor with anti-inflammatory and analgesic properties.
In well designed trials, valdecoxib demonstrated efficacy versus placebo in patients with osteoarthritis (OA), rheumatoid arthritis (RA), primary dysmenor-rhoea and postoperative pain. Initial results in patients with migraine headache were promising. The efficacy of valdecoxib appears dose dependent up to 40 mg/ day.
Valdecoxib 10 mg/day was as effective as naproxen and rofecoxib in improving signs and symptoms of OA. The American College of Rheumatology 20% response rate was similar in recipients of valdecoxib, naproxen and diclofenac in patients with RA. In patients with dysmenorrhoea, valdecoxib 20 or 40mg up to twice daily provided as effective pain relief as naproxen sodium 550mg twice daily.
In acute post-surgical pain, single-dose valdecoxib 40mg had a rapid onset of action, provided similar analgesia to oxycodone 10mg plus paracetamol (acetaminophen) 1000mg and provided a longer time to rescue medication than rofecoxib or oxycodone/paracetamol after oral surgery. Pre-emptive administration of valdecoxib 10–80mg was particularly effective in dental pain. Valdecoxib had opioid-sparing effects after hip or knee arthroplasty and reduced pain after laparoscopic cholecystectomy.
Valdecoxib is generally well tolerated. The incidence of gastroduodenal ulcers was generally lower than with nonselective NSAIDs (i.e. NSAIDs not specifically developed as selective COX-2 inhibitors). With concomitant aspirin, the ulcer rate in valdecoxib recipients increased significantly, but was still lower than that in recipients of aspirin plus nonselective NSAIDs.
In conclusion, valdecoxib, a COX-2-selective inhibitor, is as efficacious in pain relief as nonselective NSAIDs, with better gastrointestinal tolerability. It was as effective in RA, OA and primary dysmenorrhoea (the approved indications) as nonselective NSAIDs and as effective as rofecoxib in RA flare. In acute post-surgical pain, valdecoxib provided similar pain relief to oxycodone/paracetamol, had a long duration of action, a rapid onset of analgesia and was opioid-sparing. Valdecoxib provides a valuable alternative in the treatment of chronic arthritis pain and acute pain.
Valdecoxib (a ‘coxib’) is a highly selective inhibitor of cyclo-oxygenäse (C0X)-2 with anti-inflammatory and analgesic properties. This selectivity is the likely mechanism conferring the better gastrointestinal (GI) tolerability profile of coxibs relative to NSAIDs not specifically developed as selective COX-2 inhibitors (referred to here as nonselective NSAIDs). In an in vitro study, the valdecoxib concentration required to inhibit 50% of enzyme activity was 0.005 μmol/L for COX-2, but was 140 μmol/L for COX-1. Binding of valdecoxib to COX-2 is reversible and inhibited by nonselective NSAIDs. An in vitro study found valdecoxib only weakly antagonised the anti-platelet effect of aspirin.
In healthy male volunteers, valdecoxib 10 mg/day was rapidly absorbed, reaching a steady-state mean maximum plasma concentration (Cmax) of 161 ng/mL after a mean 2.25 hours (tmax). A single dose of valdecoxib 50mg reached a mean Cmax of 1040 ng/mL at a tmax of 1.7 hours. Absorption may be delayed by up to 2 hours by food. The elimination half-life of valdecoxib was ≈7–8 hours; this increased in elderly patients, with overall exposure to valdecoxib increasing by 30–40%. In patients with moderate hepatic impairment, exposure to valdecoxib is increased by 130%.
Valdecoxib is extensively metabolised via cytochrome P450 (CYP) isoenzymes, especially CYP3A4 and CYP2C9, and interacts with some drugs metabolised by CYP isoenzymes (e.g. fluconazole, dextromethorphan and omeprazole). Excretion is mainly renal (76% of a radiolabelled valdecoxib dose) and metabolites are mostly excreted via the kidney.
In healthy volunteers, coadministration of valdecoxib and warfarin significantly increased the international normalised ratio and its variability. Exposure to lithium, or ethinylestradiol/norethisterone (norethindrone) 35μg/1μg increased with coadministration of valdecoxib.
Oral valdecoxib was more effective than placebo (p < 0.05) and similar in efficacy to nonselective NSAIDs in patients with osteoarthritis (OA), rheumatoid arthritis (RA), primary dysmenorrhoea, acute postoperative pain and migraine headache in randomised, double-blind trials. ]In 12-week studies in patients with OA of the hip or knee, valdecoxib 10 or 20 mg/day generally improved global assessments (e.g. composite arthritis index scores) by 27–37% from baseline and pain assessments (e.g. patient’s perception of arthritis pain) by 26–45%, to a significantly greater extent than placebo (10–30% and 12–36%, respectively). Valdecoxib 10 or 20 mg/day had similar efficacy to naproxen 500mg twice daily (stable OA) and valdecoxib 10 mg/day was similar to rofecoxib 25 mg/day in reducing pain intensity in a 2-week study in patients with a flare of OA of the knee.
In patients with stable RA, American College of Rheumatology 20% (ACR-20) response rates and improvements in ACR-20 components were similar (32–36%) in patients receiving valdecoxib 20 or 40 mg/day or diclofenac slow release 75mg twice daily for 26 weeks. In patients experiencing an RA flare, valdecoxib 10–40 mg/day had similar efficacy to naproxen 500mg twice daily for 12 weeks and resulted in significantly better outcomes, including ACR-20 response rates (46–49%), than placebo (32%).
Valdecoxib 20 or 40mg twice daily as required for 3 days provided significant pain relief and reduced pain intensity (time weighted total of pain relief [TOTPAR] and time weighted sum of pain intensity difference) compared with placebo 8 and 12 hours after the first dose in patients with primary dysmenor-rhoea, with some dose-dependent effects evident. Naproxen sodium 550mg had similar efficacy.
In postoperative dental pain, valdecoxib 20 or 40mg (mostly single doses) was significantly better than placebo, based on onset of analgesia, 6- and 24-hour TOTPAR scores and time to rescue medication.
Preoperative valdecoxib administration was particularly effective. Postoperative pain intensity was significantly reduced versus placebo with valdecoxib 40 and 80mg administered before bunionectomy, and with parecoxib administered before laparoscopic cholecystectomy. Use of opioids reduced by 16–43% relative to placebo, and pain intensity significantly reduced in patients receiving valdecoxib 20 or 40mg twice daily following knee or hip arthroplasty.
Valdecoxib 40mg showed some advantages over rofecoxib 50mg; in one study, valdecoxib recipients had a faster onset of analgesia (<30 minutes) and, in another, had significantly higher TOTPAR scores and a significantly longer time to rescue medication. In two studies, valdecoxib 40mg was associated with significantly higher 24-hour TOTPAR scores and a significantly longer time to rescue medication than oxycodone/paracetamol.
Preliminary reports found a single dose of valdecoxib 40mg to be better than placebo in patients with moderate-to-severe migraine headache pain (resulting in mild or no pain in 48% vs 30% and relief of associated symptoms like nausea and phonophobia at 2 hours postdose). Valdecoxib 40–60mg was effective in up to three consecutive headaches and valdecoxib 20mg also significantly improved migraine pain and some other symptoms relative to placebo.
Valdecoxib was generally well tolerated in clinical trials. The incidence of headache, dizziness and fever was generally similar in recipients of valdecoxib and placebo.
GI symptoms other than ulcers had a similar incidence in valdecoxib and placebo recipients in most large, well designed trials, and the incidence of individual and total GI symptoms was similar in valdecoxib and placebo groups in a large pooled analysis. Exceptions were a higher incidence of total GI symptoms with valdecoxib 10 (but not 20) mg/day, ibuprofen and diclofenac than with placebo in a trial in patients with OA and, in patients with RA receiving a supratherapeutic dose of valdecoxib 40 mg/day for 12 weeks, significantly more dyspepsia than in those receiving placebo.
In patients with OA or RA, the incidence of endoscopically-proven gastric and gastroduodenal ulcers was significantly lower with valdecoxib 5–40 mg/day than with diclofenac, ibuprofen or naproxen (although in one trial there was no significant difference between valdecoxib 20 mg/day and naproxen).
The incidence of duodenal ulcers was significantly lower with valdecoxib 20 and 40 mg/day than with diclofenac 75mg twice daily in two studies, although no significant differences were seen between valdecoxib and other nonselective NSAIDs in the incidence of duodenal ulcers. The incidence of gastroduodenal ulcers was significantly greater in valdecoxib recipients who also used aspirin than in those who did not, although the incidence in valdecoxib plus aspirin recipients was still lower than that in nonselective NSAID plus aspirin recipients.
In a pooled analysis of eight 12- to 26-week trials in patients with OA or RA, the incidence of ulcer complications (perforation, obstruction or bleeding) was significantly lower with valdecoxib 5–80 mg/day than with nonselective NSAIDs.
In individual trials, no renal adverse effects occurred significantly more frequently in valdecoxib recipients than in other treatment groups or placebo recipients. However, a pooled analysis of almost 1000 patients with arthritis found a significantly increased incidence of renal events (mostly oedema or deterioration in blood pressure control) in patients receiving valdecoxib 10 mg/day (3%, similar to that with nonselective NSAIDs, vs 1% with placebo).
Pooled analyses of 6- to 52-week trials in >7900 arthritic patients found no difference in the incidence of thrombotic events between recipients of valdecoxib, other NSAIDs (ibuprofen, diclofenac or naproxen) and placebo.
Dosage and Administration
Valdecoxib is approved in the US and some countries in the EU for the treatment of the signs and symptoms of OA and adult RA and for primary dysmenorrhoea. Dosage recommendations, contraindications and cautions differ between the EU and the US.
In the US, the approved dosage of oral valdecoxib for the treatment of arthritis is 10mg once daily, with no dosage adjustment required in patients aged >65 years. For primary dysmenorrhoea, the approved dosage is 20mg twice daily as required. In the EU countries in which valdecoxib is approved, the dosage for arthritis is 10mg once daily up to 20mg once daily if needed; treatment should be initiated at the lower dosage in patients aged >65 years. For primary dysmenorrhoea, the approved dosage is 40mg up to twice daily on day 1 and once daily on subsequent days. p ]Clinically significant drug interactions have occurred with drugs which are metabolised by CYP isoenzymes, including CYP2D6. Caution is recommended with concomitant administration of valdecoxib and other CYP2D6 substrates that have a narrow therapeutic index (e.g. flecainide, propafenone and metoprolol). Interactions with ACE inhibitors, reducing their antihypertensive effects, and with furosemide and thiazide diuretics, reducing their natriuretic effect, may also occur.
- Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002 Dec; 32 (3 Suppl. 1): 25–32 CrossRef
- Centers for Disease Control and Prevention. Prevalence of self-reported arthritis or chronic joint symptoms among adults, United States, 2001. Morb Mortal Wkly Rep 2002 Oct 25; 51(42): 948–50
- FitzGerald G. Cardiovascular pharmacology of nonselective nonsteroidal antiinflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002 Mar 21; 89(6A): 26D–32D CrossRef
- Tacconelli S, Capone ML, Sciulli MG, et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 2002; 18(8): 503–11 CrossRef
- Ormrod D, Wellington K, Wagstaff AJ. Valdecoxib. Drugs 2002; 62(14): 2059–71; discussion 2072-3 CrossRef
- Hood WF, Gierse JK, Isakson PC, et al. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 2003 Apr; 63(4): 870–7 CrossRef
- Mengle-Gaw LJ, Schwartz BD. Cyclooxygenase-2 inhibitors: Promise or peril? Mediators Inflamm 2002; 11(5): 275–86 CrossRef
- Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000 Mar 9; 43(5): 775–7 CrossRef
- Ouellet M, Riendeau D, Percival DM. A high level of cyclooxygenase-2 inhibitior selectivity is associated with a reduced interference of platelet cyclo-oxygenase-1 incativation by aspirin. Proc Natl Acad Sci USA 2001 Dec 4; 98(25): 14583–8 CrossRef
- Muller-Decker K, Hirschner W, Marks F, et al. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol 2002 Nov; 119(5): 1189–95 CrossRef
- Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003 May; 43(5): 504–13
- Leese PT, Talwalker S, Kent JD, et al. Valdecoxib does not impair platelet function. Am J Emerg Med 2002 Jul; 20(4): 275–81 CrossRef
- Bulut D, Liaghat S, Hanefeld C, et al. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 2003 Sep; 21(9): 1663–7 CrossRef
- Ibrahim A, Karim A, Feldman J, et al. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg 2002 Sep; 95(3): 667–73
- Yuan JJ, Yang DC, Zhang JY, et al. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos 2002 Sep; 30(9): 1013–21 CrossRef
- Karim A, Bradford D, Quian M, et al. Cycoloxygenase-2 specific inhibitor valdecoxib: single and multiple dose pharmacokinetic profile in healthy adults [abstract no. 334]. Pharmacol Toxicol 2001; 89 Suppl. 1: 86
- Ibrahim AE, Feldman J, Karim A, et al. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003 Apr; 98(4): 853–61 CrossRef
- Pfizer Inc. Bextra® valdecoxib tablets. Product information [online]. Available from URL: http://www.bextra.com/pdf/bextrapi.pdf [Accessed 2003 Nov 24]
- Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002 Mar-2002 30; 9(2): 89–97 CrossRef
- Christensen K, Cawkwell G. Valdecoxib, a novel potent COX-2-specific inhibitor, is effective in treating postoperative dental pain and provides a more rapid onset of action compared with rofecoxib. Ann Emerg Med 2002 Oct; 40 Suppl.: 6–7
- Alsalameh S, Burian M, Mahr G, et al. Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2003 Feb 15; 17(4): 489–501 CrossRef
- The European Agency for the Evaluation of Medicinal Products. Bextra summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/Bextra/bextra.htm [Accessed 2003 Sep 11]
- Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002 Apr; 10(4): 290–6 CrossRef
- Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002 Jun; 51(6): 530–7
- Fiechtner JJ, Sikes D, Recker D. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee [abstract no. OP0048]. European Congress of Rheumatology; 2001 June 13; Prague, Czech Republic
- Moskowitz RW, Jones JB. Valdecoxib 10mg demonstrates a rapid onset of action following a single dose in patients with OA of the knee in a flare state [abstract no. FRI0277]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 279
- Bellamy N, Campbell J, Hill J, et al. A comparative study of telephone versus onsite completion of the WOMAC 3.0 osteoarthritis index. J Rheumatol 2002 Apr; 29(4): 783–6
- Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002 Sep; 41(9): 1008–16 CrossRef
- Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003 Oct; 42(10): 1207–15 CrossRef
- Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Invest Drugs 2002 Jul; 11(7): 927–35 CrossRef
- Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ) and a rescored 20 item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patiens following leflunomide initiation. J Rheumatol 2001 May; 28(5): 982–9
- Bensen W, Weaver A, Espinoza L, et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis [abstract no. 1896]. Arthritis Rheum 2001; 44 (9 Suppl.): 369
- Weaver A, Bensen W, Espinoza L, et al. Valdecoxib provides improved efficacy in patients with rheumatoid arthritis even when administered concomitantly to patients already taking DMARDs or low-dose corticosteroids [abstract no. 851]. Arthritis Rheum 2002 Sep; 46 Suppl.: 336
- Daniels DE, Torris S, Snabes MC. Efficacy of valdecoxib versus naproxen sodium in primary dysmenorrhea. Obstet Gynecol 2002; 99 Suppl.: 30S–1S
- Daniels SE, Talwalker S, Torri S, et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002 Aug; 100(2): 350–8 CrossRef
- Camu F, Beecher T, Recker DP, et al. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002 Jan 28; 9(1): 43–51 CrossRef
- Daniels SE, Desjardins PJ, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/ acetaminophen after oral surgery. J Am Dent Assoc 2002 May; 133(5): 611–21
- Reynolds LW, Hoo RK, Brill RJ, et al. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage 2003 Feb; 25(2): 133–41 CrossRef
- Desjardins PJ, Shu VS, Recker DP, et al. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 2002 Sep; 97(3): 565–73 CrossRef
- Joshi GP, Viscusi ER, Gan TJ, et al. Effective treatment of laparoscopic choecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 2004 Feb; 98: 336–42 CrossRef
- Daniels S, Katz J, Bandy D, et al. Analgesic efficacy of valdecoxib in oral surgery pain: a comparison of preoperative and postoperative dosing. J Pain 2003 Mar; 4 Suppl. 1: 81
- Thomas HM, Kudrow MD, Ashford EA, et al. A phase III multicenter, randomized, double-blind, parallel-group study of valdecoxib 40mg vs placebo in patients with multiple moderate or severe acute migraine headaches with or without aura [abstract]. Cephalgia 2003 Sep; 23(9): 697
- Thomas H, Le V, Brown MT. Valdecoxib effectively treats a single moderate or severe acute migraine headache [abstract no. F14]. Headache 2003 May; 43: 523–4
- Sikes DH, Agrawal NM, Zhao WW, et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002 Oct; 14(10): 1101–11 CrossRef
- Zhao S, Gan T, Joshi G, et al. Reduction of opioid use and related side effects after laparoscopic cholecystectomy surgery: another benefit of IV parecoxib sodium and oral valdecoxib in postoperative pain management [abstract no. 925]. J Pain 2003 Mar; 4 Suppl. 1: 83
- Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Internal Med 1996 Jul 22; 156(14): 1530–6 CrossRef
- Larkai E.N., Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987 Nov; 82(11): 1153–8
- Goldstein JL, Kivitz AJ, Verburg KM, et al. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 2003 Jul 1; 18(1): 125–32 CrossRef
- Eisen G, Agrawal N, Kent JD, et al. Valdecoxib has a GI safety and tolerability profile superior to nonselective NSAIDs and similar to placebo in arthritis patients under 55 years [abstract no. 334]. Arthritis Rheum 2002 Sep; 46 Suppl.: 158–9
- Goldstein JL, Kent J, Shu V, et al. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease [abstract no. M1731]. Gastroenterology 2002 Apr; 122 Suppl. 1: A344
- Goldstein JL, Stenson W, Agrawal N, et al. Valdecoxib is associated with a significantly lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID. [abstract no. T1503] Gastroenterology 2002 Apr; 122 Suppl. 1: A469 CrossRef
- Goldstein JL, Stenson WW, Agarwal N, et al. Large-scale open-label valdecoxib trials demonstrate low rate of adjucated ulcer complications [abstract no. 904]. Am J Gastroenterol 2002 Sep; 97 Suppl.: 297 CrossRef
- Wolfe F., Freundlich B, Straus WL. Increase in cardiovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003 Jan; 30(1): 36–40
- White WB, Verburg KM, Whelton A. The cyclo-oxygenase-2 specific inhibitor valdecoxib is not associated with an increased risk of cardiovascular thrombotic events in arthritis patients [abstract no. 1095-51]. J Am Coll Cardiol 2003 Mar 19; 41 (6 Suppl. A): 525A CrossRef
- Whelton A, Kent JD, Recker DP. No difference in thrombotic events in rheumatoid arthritis patients: valdecoxib vs. naproxen and placebo [abstract no. 1370]. Arthritis Rheum 2002 Sep; 46 Suppl.: 512
- The European Agency for the Evaluation of Medicinal Products. EMEA public statement on parecoxib sodium (Dynastat/ Rayzon/Xapit) risk of serious hypersensitivity and skin reactions [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pus/2517502en.pdf [Accessed 2004 Jan 22]
- Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003 Apr; 23(4): 551–3 CrossRef
- Anon. New warnings for Bextra. FDA Consum 2003 Jan-2003 28; 37(1): 5
- Grob M, Scheidegger P, Wuthrich B. Allergic skin reaction to celecoxib [letter]. Dermatology 2000; 201(4): 383 CrossRef
- Anon. Bextra Medical Review Parts 1–4 [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2001/21-341_Bextra.htm [Accessed 2003 Aug 14]
- Drukker A. Fetal and neonatal renal aspects of cyclooxygenase (COX) inhibition [letter]. Kidney Int 2002; 62(4): 1477–8 CrossRef
- National Institutes of Health: National Institute of Arthritis and Musculoskeletal and Skin Diseases. Arthritis prevalence rising as baby boomers grow older. Osteoarthritis second only to chronic heart disease in worksite disability [online]. Available from URL: http://www.niams.nih.gov/ne/press/1998/05_05.htm [Accessed 2003 Sep 23]
- Perrot S, Menkes CJ. Nonpharmacological approaches to pain in osteoarthritis: available options. Drugs 1996; 52 Suppl. 3: 21–6 CrossRef
- Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003 Apr; 48(4): 917–26 CrossRef
- Coco AS. Primary dysmenorrhoea. Am Fam Physician 1999 Aug; 60(2): 489–96
- Milsom I, Minic MM, Dawood MY, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhoea: a pooled analysis of five studies. Clin Ther 2002 Sep; 24(9): 1384–400 CrossRef
- Harlow S, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996 Nov; 103(11): 1134–42 CrossRef
- Mahmoud EA, Abdel Motaal MG, Kamal MM, et al. The relationship between pain and inflammation in patients with rheumatoid arthritis [abstract no. 92]. European League Against Rheumatism; 1999 Jun 6; Glasgow, 32
- Meisler JG. Toward optimal health: the experts discuss osteoarthritis in women. J Women Health 2002; 11(9): 759–65 CrossRef
- Staats PS. Pain management and beyond: Evolving concepts and treatments involving cyclooxygenase inhibition. J Pain Symptom Manage 2002 Jul; 24 (1 Suppl. 1): S4–9 CrossRef
- Ruoff GE. Challenges of managing chronic pain in the elderly. Semin Arthritis Rheum 2002 Dec; 32 (3 Suppl. 1): 43–50 CrossRef
- Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002 Aug; 8(8): 390–6 CrossRef
- Sinatra R. Role of COX-2 inhibitors in the evolution of acute pain management. J Pain Symptom Manage 2002 Jul; 24 (1 Suppl.): S18–27 CrossRef
- Carr DB, Goudas LC. Acute Pain. Lancet 1999 Jun 12; 353(9169): 2051–8 CrossRef
- Moote CA. The prevention of post-operative pain. Can J Anaethesia 1994 Jun; 41(6): 527–33 CrossRef
- Frenette L. The acute pain service. Crit Care Clin 1999 Jan; 15(1): 143–50 CrossRef
- Bardiau FM, Taviaux NF, Albert A, et al. An intervention study to enhance postoperative pain management. Anesth Analg 2003 Jan; 96(1): 179–85
- Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002 Dec; 32 (3 Suppl. 1): 4–14 CrossRef
- Anon. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000 Sep; 43(9): 1905–15 CrossRef
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002 Feb; 46(2): 326–46 CrossRef
- Eccles M, Freemantle N, Mason J, et al. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998 Aug 22; 317(7157): 526–30 CrossRef
- Wolfe M.M., Lichenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17; 340(24): 1888–99 CrossRef
- Goto M, Hanyu T, Yoshio T, et al. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 2001 Jul–Aug; 19(4): 377–83
- Anon. The management of chronic pain in older persons: clinical practice guidelines. AGS panel on chronic pain in older persons. Geriatrics 1998 Oct; 53 Suppl 3: s8–s23
- Greenberger NJ. Update in gastroenterology. Ann Intern Med 1997 Nov 1; 127(9): 827–34
- Markenson JA. The demographics of chronic pain management. J Pain Symptom Manage 2002 Jul; 24 (1 Suppl. 1): S10–7 CrossRef
- Centers for Disease Control and Prevention. Prevalence of aspirin use to prevent heart disease — Wisconsin, 1991, and Michigan, 1994. Morb Mortal Wkly Rep 1997 Jun 6; 46(22): 498–502
- Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. NEJM 2001 Dec 10; 345(25): 1809–17 CrossRef
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284(10): 1247–55
- Goldstein J. for the CLASS Investigators. Gastrointestinal event rates in the CLASS study: six months vs longer-term follow-up analyses [abstract no. T1504 plus poster]. Gastroenterology 2002; 122 (4 Suppl. 1): A469
- Chevenard R, Hiirlimann D, Béchir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003 Jan; 107: 405–9 CrossRef
- Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002; 62(18): 2637–51; discussion 2652-3 CrossRef
- Armstrong EP, Malone DC. The impact of nonsteroidal antiinflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003; 25(1): 1–18 CrossRef
Volume 64, Issue 11 , pp 1231-1261
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors